Sector News

AstraZeneca CEO: We want a ‘strong, science-led FDA’

February 2, 2017
Life sciences

The chief of AstraZeneca Pascal Soriot said during the Big Pharma’s financials this morning that he wants a “science-led FDA” as President Donald Trump’s administration looks to slash regulations, and potentially staff, from across the agency.

In the Q4 update call to journalists and analysts, Soriot said: “We actually believe in a strong, science-led FDA. We are a science-led organization that thrives to hit high scientific standards and so we would expect the FDA to be well staffed and focused also on those standards.”

But he said that there are always opportunities to “do things better” and so “we continue to engage with the FDA to do what that have done very successfully in oncology over the past few years, which is finding new pathways to accelerate approvals of new drugs or indications.

“If you look back over the past few years, quite a number of breakthroughs in cancer in oncology have been brought to patients in the U.S., and the oncology department [from the FDA] has been trailblazing from the point of view.”

He cautioned that there is a limit to “how fast we can go in doing those things well.”

This comes as Trump sat down with a number of Big Pharma chiefs earlier this week and said he was seeking to cut down on regulations at the FDA, and was also likely to, as part of a broader hiring freeze across the country for federal employees, reduce headcount at the agency in the coming years through attrition.

Trump said at the meeting: “We’re going to get rid of a tremendous number of regulations. We’re going to be cutting regulations like nobody has ever seen before. And we’re going to have tremendous protections for the people, perhaps even more protections for the people. We’re going to streamline the FDA.

“We have a fantastic person [to lead the Agency] that I think I will be naming very soon. We’re going to streamline the FDA. You’re going to get your products either approved or not approved but it’s going to be a quick process. It’s not going to take 15 years.”

This was largely backed by biopharma groups BIO and PhRMA, but was criticized by U.S. lawmakers.

By Ben Adams

Source: Fierce Biotech

comments closed

Related News

November 21, 2021

Johnson & Johnson to focus on pharmaceuticals

Life sciences

Johnson & Johnson has announced that it plans to separate its Consumer Health business, leaving the new Johnson & Johnson to focus on pharmaceuticals and medical devices. Alex Gorsky, current CEO, will become the Executive Chairman of the new Johnson & Johnson. Joaquin Duato, currently Vice Chairman of the Company’s Executive Committee, will become the new CEO.

November 21, 2021

Novo Nordisk to acquire Dicerna Pharmaceuticals including the RNAi research technology platform

Life sciences

Novo Nordisk today announced that it has entered into a definitive agreement to acquire Dicerna Pharmaceuticals (Dicerna). The acquisition of Dicerna’s ribonucleic acid interference (RNAi) platform is a strategic addition to Novo Nordisk’s existing research technology platforms and supports the strategy of using a broad range of technology platforms applicable across all Novo Nordisk’s therapeutic focus areas.

November 21, 2021

What are the benefits of the digital health revolution?

Life sciences

Naomi predicts that start-ups will continue to take over the healthcare industry, and Big Pharma companies will be forced to adapt to the future by partnering with small tech start-ups, or fade away due to irrelevance. Discover more of industry leader Naomi Fried’s insights as she discusses the future of healthcare with Andrew Kris of Borderless

Send this to a friend